Intestinal permeability disturbances: causes, diseases and therapy.
Gut dysbiosis
Gut permeability
Intestinal barrier
Leaky gut diseases
Zonulin
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
20
08
2024
accepted:
22
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Nowadays, a pathological increase in the permeability of the intestinal barrier (the so-called leaky gut) is increasingly being diagnosed. This condition can be caused by various factors, mainly from the external environment. Damage to the intestinal barrier entails a number of adverse phenomena: dysbiosis, translocation of microorganisms deep into the intestinal tissue, immune response, development of chronic inflammation. These phenomena can ultimately lead to a vicious cycle that promotes the development of inflammation and further damage to the barrier. Activated immune cells in mucosal tissues with broken barriers can migrate to other organs and negatively affect their functioning. Damaged intestinal barrier can facilitate the development of local diseases such as irritable bowel disease, inflammatory bowel disease or celiac disease, but also the development of systemic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, hepatitis, and lupus erythematosus, neurodegenerative or psychiatric conditions, or metabolic diseases such as diabetes or obesity. However, it must be emphasized that the causal links between a leaky gut barrier and the onset of certain diseases often remain unclear and require in-depth research. In light of recent research, it becomes crucial to prevent damage to the intestinal barrier, as well as to develop therapies for the barrier when it is damaged. This paper presents the current state of knowledge on the causes, health consequences and attempts to treat excessive permeability of the intestinal barrier.
Identifiants
pubmed: 39340718
doi: 10.1007/s10238-024-01496-9
pii: 10.1007/s10238-024-01496-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
232Informations de copyright
© 2024. The Author(s).
Références
Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21(11):739–51. https://doi.org/10.1038/s41577-021-00538-7 .
doi: 10.1038/s41577-021-00538-7
pubmed: 33846604
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, Turk M, Gorgulu Akin B, Akdis M, Altiner S, Ozbey U, Ogulur I, Mitamura Y, Yilmaz I, Nadeau K, Ozdemir C, Mungan D, Akdis CA. Epithelial barrier hypothesis: effect of the external exposome on the microbiome and epithelial barriers in allergic disease. Allergy. 2022;77(5):1418–49. https://doi.org/10.1111/all.15240 .
doi: 10.1111/all.15240
pubmed: 35108405
Cecchi L, D’Amato G, Annesi-Maesano I. External exposome and allergic respiratory and skin diseases. J Allergy Clin Immunol. 2018;141(3):846–57. https://doi.org/10.1016/j.jaci.2018.01.016 .
doi: 10.1016/j.jaci.2018.01.016
pubmed: 29519451
Sözener ZC, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. J Allergy Clin Immunol. 2020;145(6):1517–28. https://doi.org/10.1016/j.jaci.2020.04.024 .
doi: 10.1016/j.jaci.2020.04.024
Burbank AJ, Sood AK, Kesic MJ, Peden DB, Hernandez ML. Environmental determinants of allergy and asthma in early life. J Allergy Clin Immunol. 2017;140(1):1–12. https://doi.org/10.1016/j.jaci.2017.05.010 .
doi: 10.1016/j.jaci.2017.05.010
pubmed: 28673399
pmcid: 5675123
Sbihi H, Boutin RC, Cutler C, Suen M, Finlay BB, Turvey SE. Thinking bigger: how early-life environmental exposures shape the gut microbiome and influence the development of asthma and allergic disease. Allergy. 2019;74(11):2103–15. https://doi.org/10.1111/all.13812 .
doi: 10.1111/all.13812
pubmed: 30964945
Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124(1):3–20. https://doi.org/10.1016/j.jaci.2009.05.038 .
doi: 10.1016/j.jaci.2009.05.038
pubmed: 19560575
pmcid: 4266989
Aleman RS, Moncada M, Aryana KJ. Leaky gut and the ingredients that help treat it: a review. Molecules. 2023;28(2):619. https://doi.org/10.3390/molecules28020619 .
doi: 10.3390/molecules28020619
pubmed: 36677677
pmcid: 9862683
Brandl C, Bucci L, Schett G, Zaiss MM. Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis. Eur J Immunol. 2021;51(4):798–810. https://doi.org/10.1002/eji.202048876 .
doi: 10.1002/eji.202048876
pubmed: 33594693
Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism. J Gastroenterol Hepatol. 2013;28(Suppl 4):9–17. https://doi.org/10.1111/jgh.12294 .
doi: 10.1111/jgh.12294
pubmed: 24251697
Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016;535(7610):85–93. https://doi.org/10.1038/nature18849 .
doi: 10.1038/nature18849
pubmed: 27383983
pmcid: 5114849
Ostaff MJ, Stange EF, Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med. 2013;5(10):1465–83. https://doi.org/10.1002/emmm.201201773 .
doi: 10.1002/emmm.201201773
pubmed: 24039130
pmcid: 3799574
Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol. 2012;15(1):57–62. https://doi.org/10.1016/j.mib.2011.11.002 .
doi: 10.1016/j.mib.2011.11.002
pubmed: 22177113
Gerbe F, Legraverend C, Jay P. The intestinal epithelium tuft cells: specification and function. Cell Mol Life Sci. 2012;69(17):2907–17. https://doi.org/10.1007/s00018-012-0984-7 .
doi: 10.1007/s00018-012-0984-7
pubmed: 22527717
pmcid: 3417095
Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009;1(2):a002584. https://doi.org/10.1101/cshperspect.a002584 .
doi: 10.1101/cshperspect.a002584
pubmed: 20066090
pmcid: 2742087
Drąg J, Goździalska A, Knapik-Czajka M, Matuła A, Jaśkiewicz J. Nieszczelność jelit w chorobach autoimmunologicznych. Państwo i Społeczeństwo. 2017;17(4):133–46.
Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516–26. https://doi.org/10.1136/gutjnl-2019-318427 .
doi: 10.1136/gutjnl-2019-318427
pubmed: 31076401
Wood Heickman LK, DeBoer MD, Fasano A. Zonulin as a potential putative biomarker of risk for shared type 1 diabetes and celiac disease autoimmunity. Diabetes Metab Res Rev. 2020;36(5):e3309. https://doi.org/10.1002/dmrr.3309 .
doi: 10.1002/dmrr.3309
pubmed: 32162764
pmcid: 7340576
Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):1–9. https://doi.org/10.1038/s12276-018-0126-x .
doi: 10.1038/s12276-018-0126-x
pubmed: 30115904
Wright SL, Kelly FJ. Plastic and human health: a micro issue? Environ Sci Technol. 2017;51(12):6634–47. https://doi.org/10.1021/acs.est.7b00423 .
doi: 10.1021/acs.est.7b00423
pubmed: 28531345
Yee M-L, Hii L-W, Looi CK, et al. Impact of microplastics and nanoplastics on human health. Nanomaterials. 2021;11(2):496. https://doi.org/10.3390/nano11020496 .
doi: 10.3390/nano11020496
pubmed: 33669327
pmcid: 7920297
Holloczki O, Gehrke S. Can nanoplastics alter cell membranes? ChemPhysChem. 2020;21(1):9–12. https://doi.org/10.1002/cphc.201900481 .
doi: 10.1002/cphc.201900481
pubmed: 31483076
Holloczki O, Gehrke S. Nanoplastics can change the secondary structure of proteins. Sci Rep. 2019;9(1):16013. https://doi.org/10.1038/s41598-019-52495-w .
doi: 10.1038/s41598-019-52495-w
pubmed: 31690820
pmcid: 6831684
Xu M, Halimu G, Zhang Q, Song Y, Fu X, Li Y, Li Y, Zhang H. Internalization and toxicity: a preliminary study of effects of nanoplastic particles on human lung epithelial cell. Sci Total Environ. 2019;694:133794. https://doi.org/10.1016/j.scitotenv.2019.133794 .
doi: 10.1016/j.scitotenv.2019.133794
pubmed: 31756791
Jin Y, Lu L, Tu W, Luo T, Fu Z. Impacts of polystyrene microplastic on the gut barrier, microbiota and metabolism of mice. Sci Total Environ. 2019;649:308–17. https://doi.org/10.1016/j.scitotenv.2018.08.353 .
doi: 10.1016/j.scitotenv.2018.08.353
pubmed: 30176444
Vietti G, Lison D, van den Brule S. Mechanisms of lung fibrosis induced by carbon nanotubes: towards an adverse outcome pathway (AOP). Part Fibre Toxicol. 2016;13:11. https://doi.org/10.1186/s12989-016-0123-y .
doi: 10.1186/s12989-016-0123-y
pubmed: 26926090
pmcid: 4772332
Chakraborty S, Castranova V, Perez MK, Piedimonte G. Nanoparticles-induced apoptosis of human airway epithelium is mediated by proNGF/p75(NTR) signaling. J Toxicol Environ Health A. 2017;80(1):53–68. https://doi.org/10.1080/15287394.2016.1238329 .
doi: 10.1080/15287394.2016.1238329
pubmed: 28140833
pmcid: 5597962
Urbančič I, Garvas M, Kokot B, Majaron H, Umek P, Cassidy H, Škarabot M, Schneider F, Galiani S, Arsov Z, Koklic T, Matallanas D, Čeh M, Muševič I, Eggeling C, Štrancar J. Nanoparticles can wrap epithelial cell membranes and relocate them across the epithelial cell layer. Nano Lett. 2018;18(8):5294–305. https://doi.org/10.1021/acs.nanolett.8b02291 .
doi: 10.1021/acs.nanolett.8b02291
pubmed: 30039976
pmcid: 6089500
Lim SL, Ng CT, Zou L, Lu Y, Chen J, Bay BH, Shen HM, Ong CN. Targeted metabolomics reveals differential biological effects of nanoplastics and nanoZnO in human lung cells. Nanotoxicology. 2019;13(8):1117–32. https://doi.org/10.1080/17435390.2019.1640913 .
doi: 10.1080/17435390.2019.1640913
pubmed: 31272252
Kogawa AC, Cernic BG, do Couto LGD, Salgado HRN. Synthetic detergents: 100 years of history. Saudi Pharm J. 2017;25(6):934–8. https://doi.org/10.1016/j.jsps.2017.02.006 .
doi: 10.1016/j.jsps.2017.02.006
pubmed: 28951681
pmcid: 5605839
Wang M, Tan G, Eljaszewicz A, Meng Y, Wawrzyniak P, Acharya S, Altunbulakli C, Westermann P, Dreher A, Yan L, Wang C, Akdis M, Zhang L, Nadeau KC, Akdis CA. Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells. J Allergy Clin Immunol. 2019;143(5):1892–903. https://doi.org/10.1016/j.jaci.2018.11.016 .
doi: 10.1016/j.jaci.2018.11.016
pubmed: 30500342
Xian M, Wawrzyniak P, Rückert B, Duan S, Meng Y, Sokolowska M, Globinska A, Zhang L, Akdis M, Akdis CA. Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. J Allergy Clin Immunol. 2016;138(3):890-893.e9. https://doi.org/10.1016/j.jaci.2016.07.003 .
doi: 10.1016/j.jaci.2016.07.003
pubmed: 27596709
Viennois E, Chassaing B. First victim, later aggressor: How the intestinal microbiota drives the pro-inflammatory effects of dietary emulsifiers? Gut Microbes. 2018;9(3):1–4. https://doi.org/10.1080/19490976.2017.1421885 .
doi: 10.1080/19490976.2017.1421885
pubmed: 29437527
Pressman P, Clemens R, Hayes W, Reddy C. Food additive safety: a review of toxicologic and regulatory issues. Toxicol Res Appl. 2017;1:1–22.
Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, Gewirtz AT. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92–6. https://doi.org/10.1038/nature14232 .
doi: 10.1038/nature14232
pubmed: 25731162
pmcid: 4910713
Krempski JW, Dant C, Nadeau KC. The origins of allergy from a systems approach. Ann Allergy Asthma Immunol. 2020;125(5):507–16. https://doi.org/10.1016/j.anai.2020.07.013 .
doi: 10.1016/j.anai.2020.07.013
pubmed: 32702411
Fiuza BSD, Fonseca HF, Meirelles PM, Marques CR, da Silva TM, Figueiredo CA. Understanding asthma and allergies by the lens of biodiversity and epigenetic changes. Front Immunol. 2021;12:623737. https://doi.org/10.3389/fimmu.2021.623737 .
doi: 10.3389/fimmu.2021.623737
pubmed: 33732246
pmcid: 7957070
Lunjani N, Satitsuksanoa P, Lukasik Z, Sokolowska M, Eiwegger T, O’Mahony L. Recent developments and highlights in mechanisms of allergic diseases: microbiome. Allergy. 2018;73(12):2314–27. https://doi.org/10.1111/all.13634 .
doi: 10.1111/all.13634
pubmed: 30325537
Haahtela T, Holgate S, Pawankar R, Akdis CA, Benjaponpitak S, Caraballo L, Demain J, Portnoy J, von Hertzen L, WAO Special Committee on Climate Change and Biodiversity. The biodiversity hypothesis and allergic disease: world allergy organization position statement. World Allergy Organ J. 2013;6(1):3. https://doi.org/10.1186/1939-4551-6-3 .
doi: 10.1186/1939-4551-6-3
pubmed: 23663440
pmcid: 3646540
Altunbulakli C, Reiger M, Neumann AU, Garzorz-Stark N, Fleming M, Huelpuesch C, Castro-Giner F, Eyerich K, Akdis CA, Traidl-Hoffmann C. Relations between epidermal barrier dysregulation and Staphylococcus species-dominated microbiome dysbiosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2018;142(5):1643-1647.e12. https://doi.org/10.1016/j.jaci.2018.07.005 .
doi: 10.1016/j.jaci.2018.07.005
pubmed: 30048670
Altunbulakli C, Costa R, Lan F, Zhang N, Akdis M, Bachert C, Akdis CA. Staphylococcus aureus enhances the tight junction barrier integrity in healthy nasal tissue, but not in nasal polyps. J Allergy Clin Immunol. 2018;142(2):665-668.e8. https://doi.org/10.1016/j.jaci.2018.01.046 .
doi: 10.1016/j.jaci.2018.01.046
pubmed: 29518417
Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71(6):1216–28. https://doi.org/10.1016/j.jhep.2019.08.005 .
doi: 10.1016/j.jhep.2019.08.005
pubmed: 31419514
pmcid: 6880766
Kim YC, Won HK, Lee JW, Sohn KH, Kim MH, Kim TB, Chang YS, Lee BJ, Cho SH, Bachert C, Song WJ. Staphylococcus aureus nasal colonization and asthma in adults: systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(2):606-615.e9. https://doi.org/10.1016/j.jaip.2018.08.020 .
doi: 10.1016/j.jaip.2018.08.020
pubmed: 30193937
Kim JW, Kwok SK, Choe JY, Park SH. Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus. Int J Mol Sci. 2019;20(19):4871. https://doi.org/10.3390/ijms20194871 .
doi: 10.3390/ijms20194871
pubmed: 31575045
pmcid: 6801612
Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K, Mohammed M, Handberg EM, Richards EM, Pepine CJ, Raizada MK. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci. 2018;132(6):701–18. https://doi.org/10.1042/CS20180087 .
doi: 10.1042/CS20180087
Søyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, Helland S, Middelfart K, Odu S, Falk ES, et al. Dietary supplementation with very long-chain n-3 fatty acids in patients with atopic dermatitis: a double-blind, multicentre study. Br J Dermatol. 1994;130(6):757–64. https://doi.org/10.1111/j.1365-2133.1994.tb03414.x .
doi: 10.1111/j.1365-2133.1994.tb03414.x
pubmed: 8011502
Hussain M, Bonilla-Rosso G, Kwong Chung CKC, Bäriswyl L, Rodriguez MP, Kim BS, Engel P, Noti M. High dietary fat intake induces a microbiota signature that promotes food allergy. J Allergy Clin Immunol. 2019;144(1):157-170.e8. https://doi.org/10.1016/j.jaci.2019.01.043 .
doi: 10.1016/j.jaci.2019.01.043
pubmed: 30768991
Yamashita H, Matsuhara H, Miotani S, Sako Y, Matsui T, Tanaka H, Inagaki N. Artificial sweeteners and mixture of food additives cause to break oral tolerance and induce food allergy in murine oral tolerance model for food allergy. Clin Exp Allergy. 2017;47(9):1204–13. https://doi.org/10.1111/cea.12928 .
doi: 10.1111/cea.12928
pubmed: 28370609
Venter C, Meyer RW, Nwaru BI, Roduit C, Untersmayr E, Adel-Patient K, Agache I, Agostoni C, Akdis CA, Bischoff SC, du Toit G, Feeney M, Frei R, Garn H, Greenhawt M, Hoffmann-Sommergruber K, Lunjani N, Maslin K, Mills C, Muraro A, Pali-Schöll I, Poulson LK, Reese I, Renz H, Roberts GC, Smith P, Smolinska S, Sokolowska M, Stanton C, Vlieg-Boerstra B, O’Mahony L. EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis. Allergy. 2019;74(8):1429–44. https://doi.org/10.1111/all.13764 .
doi: 10.1111/all.13764
pubmed: 31032983
Miles EA, Calder PC. Omega-6 and omega-3 polyunsaturated fatty acids and allergic diseases in infancy and childhood. Curr Pharm Des. 2014;20(6):946–53. https://doi.org/10.2174/138161282006140220125732 .
doi: 10.2174/138161282006140220125732
pubmed: 23701554
Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids. 2018;132:41–8. https://doi.org/10.1016/j.plefa.2018.03.004 .
doi: 10.1016/j.plefa.2018.03.004
pubmed: 29610056
Dainichi T, Kitoh A, Otsuka A, Nakajima S, Nomura T, Kaplan DH, Kabashima K. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat Immunol. 2018;19(12):1286–98. https://doi.org/10.1038/s41590-018-0256-2 .
doi: 10.1038/s41590-018-0256-2
pubmed: 30446754
Rook GA, Adams V, Hunt J, Palmer R, Martinelli R, Brunet LR. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol. 2004;25(3–4):237–55. https://doi.org/10.1007/s00281-003-0148-9 .
doi: 10.1007/s00281-003-0148-9
pubmed: 15007629
Panelli S, Epis S, Cococcioni L, Perini M, Paroni M, Bandi C, Drago L, Zuccotti GV. Inflammatory bowel diseases, the hygiene hypothesis and the other side of the microbiota: parasites and fungi. Pharmacol Res. 2020;159:104962. https://doi.org/10.1016/j.phrs.2020.104962 .
doi: 10.1016/j.phrs.2020.104962
pubmed: 32480001
Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a danger signal for autoimmune diseases. Front Immunol. 2017;8:598. https://doi.org/10.3389/fimmu.2017.00598 .
doi: 10.3389/fimmu.2017.00598
pubmed: 28588585
pmcid: 5440529
Soderholm AT, Pedicord VA. Intestinal epithelial cells: at the interface of the microbiota and mucosal immunity. Immunology. 2019;158(4):267–80. https://doi.org/10.1111/imm.13117 .
doi: 10.1111/imm.13117
pubmed: 31509239
pmcid: 6856932
Meng X, Zhou HY, Shen HH, Lufumpa E, Li XM, Guo B, Li BZ. Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity. Autoimmun Rev. 2019;18(5):455–75. https://doi.org/10.1016/j.autrev.2019.03.006 .
doi: 10.1016/j.autrev.2019.03.006
pubmed: 30844549
Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3(3):207–15. https://doi.org/10.1016/S2213-8587(14)70134-2 .
doi: 10.1016/S2213-8587(14)70134-2
pubmed: 25066177
Dutta SK, Verma S, Jain V, Surapaneni BK, Vinayek R, Phillips L, Nair PP. Parkinson’s disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation. J Neurogastroenterol Motil. 2019;25(3):363–76. https://doi.org/10.5056/jnm19044 .
doi: 10.5056/jnm19044
pubmed: 31327219
pmcid: 6657920
Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? Acta Neuropathol. 2018;136(3):345–61. https://doi.org/10.1007/s00401-018-1856-5 .
doi: 10.1007/s00401-018-1856-5
pubmed: 29797112
Tanoue T, Umesaki Y, Honda K. Immune responses to gut microbiota-commensals and pathogens. Gut Microbes. 2010;1(4):224–33. https://doi.org/10.4161/gmic.1.4.12613 .
doi: 10.4161/gmic.1.4.12613
pubmed: 21327029
pmcid: 3023604
Chunxi L, Haiyue L, Yanxia L, Jianbing P, Jin S. The gut microbiota and respiratory diseases: new evidence. J Immunol Res. 2020;2020:2340670. https://doi.org/10.1155/2020/2340670 .
doi: 10.1155/2020/2340670
pubmed: 32802893
pmcid: 7415116
Ventura MT, Polimeno L, Amoruso AC, Gatti F, Annoscia E, Marinaro M, Di Leo E, Matino MG, Buquicchio R, Bonini S, Tursi A, Francavilla A. Intestinal permeability in patients with adverse reactions to food. Dig Liver Dis. 2006;38(10):732–6. https://doi.org/10.1016/j.dld.2006.06.012 .
doi: 10.1016/j.dld.2006.06.012
pubmed: 16880015
Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, Antalis TM, Vogel SN, Zhao A, Yang S, Arrietta MC, Meddings JB, Fasano A. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. 2009;106(39):16799–804. https://doi.org/10.1073/pnas.0906773106 .
doi: 10.1073/pnas.0906773106
pubmed: 19805376
pmcid: 2744629
Ciccia F, Guggino G, Rizzo A, Alessandro R, Luchetti MM, Milling S, Saieva L, Cypers H, Stampone T, Di Benedetto P, Gabrielli A, Fasano A, Elewaut D, Triolo G. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76(6):1123–32. https://doi.org/10.1136/annrheumdis-2016-210000 .
doi: 10.1136/annrheumdis-2016-210000
pubmed: 28069576
El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, Catassi C, Fasano A. (2002) Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 123(5):1607–15. https://doi.org/10.1053/gast.2002.36578 . Erratum in: 2003, Gastroenterology124(1):275.
Lammers KM, Lammers KM, Lu R, Brownley J, Lu B, Gerard C, Thomas K, Rallabhandi P, Shea-Donohue T, Tamiz A, Alkan S, Netzel-Arnett S, Antalis T, Vogel SN, Fasano A. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135(1):194-204.e3. https://doi.org/10.1053/j.gastro.2008.03.023 .
doi: 10.1053/j.gastro.2008.03.023
pubmed: 18485912
Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. 2016;4(4):e1251384. https://doi.org/10.1080/21688370.2016.1251384 .
doi: 10.1080/21688370.2016.1251384
pubmed: 28123927
pmcid: 5214347
Sturgeon C, Lan J, Fasano A. Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model. Ann NY Acad Sci. 2017;1397(1):130–42. https://doi.org/10.1111/nyas.13343 .
doi: 10.1111/nyas.13343
pubmed: 28423466
Romero-Figueroa MDS, Ramírez-Durán N, Montiel-Jarquín AJ, Horta-Baas G. Gut-joint axis: Gut dysbiosis can contribute to the onset of rheumatoid arthritis via multiple pathways. Front Cell Infect Microbiol. 2023;13:1092118. https://doi.org/10.3389/fcimb.2023.1092118 .
doi: 10.3389/fcimb.2023.1092118
pubmed: 36779190
pmcid: 9911673
Xu X, Wang M, Wang Z, Chen Q, Chen X, Xu Y, Dai M, Wu B, Li Y. The bridge of the gut-joint axis: Gut microbial metabolites in rheumatoid arthritis. Front Immunol. 2022;13:1007610. https://doi.org/10.3389/fimmu.2022.1007610 .
doi: 10.3389/fimmu.2022.1007610
pubmed: 36275747
pmcid: 9583880
Audo R, Sanchez P, Rivière B, Mielle J, Tan J, Lukas C, Macia L, Morel J, Immediato Daien C. Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control. Rheumatology. 2022. https://doi.org/10.1093/rheumatology/keac454 .
doi: 10.1093/rheumatology/keac454
pubmed: 35947472
Tajik N, Frech M, Schulz O, Schälter F, Lucas S, Azizov V, Dürholz K, Steffen F, Omata Y, Rings A, Bertog M, Rizzo A, Iljazovic A, Basic M, Kleyer A, Culemann S, Krönke G, Luo Y, Überla K, Gaipl US, Frey B, Strowig T, Sarter K, Bischoff SC, Wirtz S, Cañete JD, Ciccia F, Schett G, Zaiss MM. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020;11(1):1995. https://doi.org/10.1038/s41467-020-15831-7 .
doi: 10.1038/s41467-020-15831-7
pubmed: 32332732
pmcid: 7181728
Ciccia F, Rizzo A, Triolo G. Subclinical gut inflammation in ankylosing spondylitis. Curr Opin Rheumatol. 2016;28(1):89–96. https://doi.org/10.1097/BOR.0000000000000239 .
doi: 10.1097/BOR.0000000000000239
pubmed: 26599385
Ciccia CF, Ferrante A, Triolo G. Intestinal dysbiosis and innate immune responses in axial spondyloarthritis. Curr Opin Rheumatol. 2016;28(4):352–8. https://doi.org/10.1097/BOR.0000000000000296 .
doi: 10.1097/BOR.0000000000000296
pubmed: 27214393
Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151–75. https://doi.org/10.1152/physrev.00003.2008 .
doi: 10.1152/physrev.00003.2008
pubmed: 21248165
Miranda-Ribera A, Miranda-Ribera A, Ennamorati M, Serena G, Cetinbas M, Lan J, Sadreyev RI, Jain N, Fasano A, Fiorentino M. Exploiting the zonulin mouse model to establish the role of primary impaired gut barrier function on microbiota composition and immune profiles. Front Immunol. 2019;10:2233. https://doi.org/10.3389/fimmu.2019.02233 .
doi: 10.3389/fimmu.2019.02233
pubmed: 31608059
pmcid: 6761304
Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Motola DL, Luther S, Bohr S, Jeoung SW, Deshpande V, Singh G, Turner JR, Yarmush ML, Chung RT, Patel SJ. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol. 2015;1(2):222–32. https://doi.org/10.1016/j.jcmgh.2015.01.001 .
doi: 10.1016/j.jcmgh.2015.01.001
pubmed: 26405687
pmcid: 4578658
Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018;12(7):641–56. https://doi.org/10.1080/17474124.2018.1481747 .
doi: 10.1080/17474124.2018.1481747
pubmed: 29806487
Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184. https://doi.org/10.1177/1758835919848184 .
doi: 10.1177/1758835919848184
pubmed: 31205505
pmcid: 6535703
Spadoni I, Fornasa G, Rescigno M. Organ-specific protection mediated by cooperation between vascular and epithelial barriers. Nat Rev Immunol. 2017;17(12):761–73. https://doi.org/10.1038/nri.2017.100 .
doi: 10.1038/nri.2017.100
pubmed: 28869253
Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14(3):141–53. https://doi.org/10.1038/nri3608 .
doi: 10.1038/nri3608
pubmed: 24566914
Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161(3):653–60. https://doi.org/10.1083/jcb.200302070 .
doi: 10.1083/jcb.200302070
pubmed: 12743111
pmcid: 2172943
Acharya NK, Qi X, Goldwaser EL, Godsey GA, Wu H, Kosciuk MC, Freeman TA, Macphee CH, Wilensky RL, Venkataraman V, Nagele RG. Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: Beneficial effects of the LpPLA
doi: 10.1177/1479164116683149
pubmed: 28301218
Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, Han X, Huang Y, Zhao L, Li P, Fang Z, Zhou J, Guan X, Ding Y, Wang S, Khan M, Xin Y, Li S, Ma Y. Alterations of the gut microbiome in hypertension. Front Cell Infect Microbiol. 2017;7:381. https://doi.org/10.3389/fcimb.2017.00381 .
doi: 10.3389/fcimb.2017.00381
pubmed: 28884091
pmcid: 5573791
Yang Z, Wang Q, Liu Y, Wang L, Ge Z, Li Z, Feng S, Wu C. Gut microbiota and hypertension: association, mechanisms and treatment. Clin Exp Hypertens. 2023;45(1):2195135. https://doi.org/10.1080/10641963.2023.2195135 .
doi: 10.1080/10641963.2023.2195135
pubmed: 36994745
Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W, Weldon R, Auguste K, Yang L, Liu X, Chen L, Yang X, Zhu B, Cai J. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. https://doi.org/10.1186/s40168-016-0222-x .
doi: 10.1186/s40168-016-0222-x
pubmed: 28143587
pmcid: 5286796
Lin D. Assocation between hypertension and impairment of intestinal barrier function. Guangzhong: Guangdong Pharmaceutical University; 2019.
Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, Cole-Jeffrey CT, Lobaton GO, Stewart DC, Rubiano A, Simmons CS, Garcia-Pereira F, Johnson RD, Pepine CJ, Raizada MK. Hypertension-linked pathophysiological alterations in the gut. Circ Res. 2017;120(2):312–23. https://doi.org/10.1161/CIRCRESAHA .
doi: 10.1161/CIRCRESAHA
pubmed: 27799253
Manner IW, Baekken M, Kvale D, Oektedalen O, Pedersen M, Nielsen SD, Nowak P, Os I, Troseid M. Markers of microbial translocation predict hypertension in HIV-infected individuals. HIV Med. 2013;14(6):354–61. https://doi.org/10.1111/hiv.12015 .
doi: 10.1111/hiv.12015
pubmed: 23332095
Jaworska K, Huc T, Samborowska E, Dobrowolski L, Bielinska K, Gawlak M, Ufnal M, Chamaillard M. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS ONE. 2017;12(12):e0189310. https://doi.org/10.1371/journal.pone.0189310 .
doi: 10.1371/journal.pone.0189310
pubmed: 29236735
pmcid: 5728578
Quigley EM. Leaky gut: concept or clinical entity? Curr Opin Gastroenterol. 2016;32(2):74–9. https://doi.org/10.1097/MOG.0000000000000243 .
doi: 10.1097/MOG.0000000000000243
pubmed: 26760399
Turner JR, Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14(1):9–21. https://doi.org/10.1038/nrgastro.2016.169 .
doi: 10.1038/nrgastro.2016.169
pubmed: 27848962
Michielan A, Michielan A, Dincà R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015. https://doi.org/10.1155/2015/628157 .
doi: 10.1155/2015/628157
pubmed: 26582965
pmcid: 4637104
Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal barrier in human health and disease. Int J Environ Res Public Health. 2021;18(23):12836. https://doi.org/10.3390/ijerph182312836 .
doi: 10.3390/ijerph182312836
pubmed: 34886561
pmcid: 8657205
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–9. https://doi.org/10.3748/wjg.v20.i1.91 .
doi: 10.3748/wjg.v20.i1.91
pubmed: 24415861
pmcid: 3886036
de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm. 2015;2015:493012. https://doi.org/10.1155/2015/493012 .
doi: 10.1155/2015/493012
pubmed: 26339135
pmcid: 4539174
Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1–10. https://doi.org/10.1007/s12328-017-0813-5 .
doi: 10.1007/s12328-017-0813-5
pubmed: 29285689
Mehandru S, Colombel JF. The intestinal barrier, an arbitrator turned provocateur in IBD. Nat Rev Gastroenterol Hepatol. 2021;18(2):83–4. https://doi.org/10.1038/s41575-020-00399-w .
doi: 10.1038/s41575-020-00399-w
pubmed: 33318680
Turpin W, Lee SH, Raygoza Garay JA, Madsen KL, Meddings JB, Bedrani L, Power N, Espin-Garcia O, Xu W, Smith MI, Griffiths AM, Moayyedi P, Turner D, Seidman EG, Steinhart AH, Marshall JK, Jacobson K, Mack D, Huynh H, Bernstein CN, Paterson AD, Croitoru K, Crohn’s and Colitis Canada Genetic Environmental Microbial Project Research Consortium; CCC GEM Project recruitment site directors include Maria Abreu. Increased intestinal permeability is associated with later development of crohn’s disease. Gastroenterology. 2020;159(6):2092-2100.e5. https://doi.org/10.1053/j.gastro.2020.08.005 .
doi: 10.1053/j.gastro.2020.08.005
pubmed: 32791132
Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis. 2010;28(6):737–44. https://doi.org/10.1159/000324281 .
doi: 10.1159/000324281
pubmed: 21525758
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–77. https://doi.org/10.1016/j.jhep.2019.10.003 .
doi: 10.1016/j.jhep.2019.10.003
pubmed: 31622696
Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R (2017) Targeting the gut-liver axis in liver disease. J Hepatol. Nov;67(5):1084–1103. https://doi.org/10.1016/j.jhep.2017.05.007 . Erratum in: J Hepatol. 2018.
Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209. https://doi.org/10.1016/j.jhep.2013.07.044 .
doi: 10.1016/j.jhep.2013.07.044
pubmed: 23993913
J Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R (2018) The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 15(7):397–411. https://doi.org/10.1038/s41575-018-0011-z . Erratum in: Nat Rev Gastroenterol Hepatol. 2018.
Bishehsari F, Magno E, Swanson G, Desai V, Voigt RM, Forsyth CB, Keshavarzian A. Alcohol and gut-derived inflammation. Alcohol Res. 2017;38(2):163–71.
pubmed: 28988571
pmcid: 5513683
Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol. 1999;94(1):200–7. https://doi.org/10.1111/j.1572-0241.1999.00797.x .
doi: 10.1111/j.1572-0241.1999.00797.x
pubmed: 9934756
Maccioni L, Gao B, Leclercq S, Pirlot B, Horsmans Y, De Timary P, Leclercq I, Fouts D, Schnabl B, Stärkel P. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes. 2020;12(1):1782157. https://doi.org/10.1080/19490976.2020.1782157 .
doi: 10.1080/19490976.2020.1782157
pubmed: 32588725
pmcid: 7524402
Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology. 2009;73(21):1752–8. https://doi.org/10.1212/WNL.0b013e3181c34af5 .
doi: 10.1212/WNL.0b013e3181c34af5
pubmed: 19933976
pmcid: 2788809
Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH. Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord. 2012;27(6):709–15. https://doi.org/10.1002/mds.23838 .
doi: 10.1002/mds.23838
pubmed: 21766334
Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models parkinson’s disease. Neuron. 2019;103(4):627-641.e7. https://doi.org/10.1016/j.neuron.2019.05.035 .
doi: 10.1016/j.neuron.2019.05.035
pubmed: 31255487
pmcid: 6706297
Buie T, Campbell DB, Fuchs GJ 3rd, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, Winter H. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl 1):S1-18. https://doi.org/10.1542/peds.2009-1878C .
doi: 10.1542/peds.2009-1878C
pubmed: 20048083
Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, Krajmalnik-Brown R. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS ONE. 2013;8(7):e68322. https://doi.org/10.1371/journal.pone.0068322 .
doi: 10.1371/journal.pone.0068322
pubmed: 23844187
pmcid: 3700858
Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, Kelly DL, Cascella N, Fasano A. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism. 2016;7:49. https://doi.org/10.1186/s13229-016-0110-z .
doi: 10.1186/s13229-016-0110-z
pubmed: 27957319
pmcid: 5129651
Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, Jousson O, Leoncini S, Renzi D, Calabrò A, De Filippo C. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017;5(1):24. https://doi.org/10.1186/s40168-017-0242-1 .
doi: 10.1186/s40168-017-0242-1
pubmed: 28222761
pmcid: 5320696
Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, Herrema H. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:571731. https://doi.org/10.3389/fimmu.2020.571731 .
doi: 10.3389/fimmu.2020.571731
pubmed: 33178196
pmcid: 7596417
Massier L, Chakaroun R, Tabei S, Crane A, Didt KD, Fallmann J, von Bergen M, Haange SB, Heyne H, Stumvoll M, Gericke M, Dietrich A, Blüher M, Musat N, Kovacs P. Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes. Gut. 2020;69(10):1796–806. https://doi.org/10.1136/gutjnl-2019-320118 .
doi: 10.1136/gutjnl-2019-320118
pubmed: 32317332
Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81. https://doi.org/10.2337/db07-1403 .
doi: 10.2337/db07-1403
pubmed: 18305141
Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Bork P, Wang J, Ehrlich SD, Pedersen O, MetaHIT consortium. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541–6. https://doi.org/10.1038/nature12506 .
doi: 10.1038/nature12506
pubmed: 23985870
Schoultz I, Keita ÅV. The intestinal barrier and current techniques for the assessment of gut permeability. Cells. 2020;9(8):1909. https://doi.org/10.3390/cells9081909 .
doi: 10.3390/cells9081909
pubmed: 32824536
pmcid: 7463717
Cai Z, Wang S, Li. Treatment of inflammatory bowel disease: a comprehensive review. Front Med (Lausanne). 2021;8:765474. https://doi.org/10.3389/fmed.2021.765474 .
doi: 10.3389/fmed.2021.765474
pubmed: 34988090
Chang S, Murphy M, Malter L. A review of available medical therapies to treat moderate-to-severe inflammatory bowel disease. Am J Gastroenterol. 2024;119(1):55–80. https://doi.org/10.14309/ajg.0000000000002485 .
doi: 10.14309/ajg.0000000000002485
pubmed: 37615291
TriantafillidisJK ZCG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: present status and future perspectives. World J Gastroenterol. 2024;30(15):2068–80. https://doi.org/10.3748/wjg.v30.i15.2068 .
doi: 10.3748/wjg.v30.i15.2068
Michielan A, D’Incà R. intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015. https://doi.org/10.1155/2015/628157 .
doi: 10.1155/2015/628157
pubmed: 26582965
pmcid: 4637104
Perez-Diaz-Del-Campo N, Castelnuovo G, Ribaldone DG, Caviglia GP. Fecal and circulating biomarkers for the non-invasive assessment of intestinal permeability. Diagnostics (Basel). 2023;13(11):1976. https://doi.org/10.3390/diagnostics13111976 .
doi: 10.3390/diagnostics13111976
pubmed: 37296827
Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, Haitchi HM, Vernon-Wilson E, Sammut D, Bedke N, Cremin C, Sones J, Djukanović R, Howarth PH, Collins JE, Holgate ST, Monk P, Davies DE. Defective epithelial barrier function in asthma. J Allergy Clin Immunol. 2011;128(3):549-56.e1. https://doi.org/10.1016/j.jaci.2011.05.038 .
doi: 10.1016/j.jaci.2011.05.038
pubmed: 21752437
De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773-86.e1. https://doi.org/10.1016/j.jaci.2010.10.018 .
doi: 10.1016/j.jaci.2010.10.018
pubmed: 21163515
Wawrzyniak P, Wawrzyniak M, Wanke K, Sokolowska M, Bendelja K, Rückert B, Globinska A, Jakiela B, Kast JI, Idzko M, Akdis M, Sanak M, Akdis CA. Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. J Allergy Clin Immunol. 2017;139(1):93–103. https://doi.org/10.1016/j.jaci.2016.03.050 .
doi: 10.1016/j.jaci.2016.03.050
pubmed: 27312821
Kubo T, Wawrzyniak P, Morita H, Sugita K, Wanke K, Kast JI, Altunbulakli C, Rückert B, Jakiela B, Sanak M, Akdis M, Akdis CA. CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier. J Allergy Clin Immunol. 2015. https://doi.org/10.1016/j.jaci.2015.05.006 .
doi: 10.1016/j.jaci.2015.05.006
pubmed: 26100085
pmcid: 4562879
Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Léotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104(Suppl 2):S1-63. https://doi.org/10.1017/S0007114510003363 .
doi: 10.1017/S0007114510003363
pubmed: 20920376
Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc. 2006;106(10):1631–9. https://doi.org/10.1016/j.jada.2006.07.010 .
doi: 10.1016/j.jada.2006.07.010
pubmed: 17000196
Tuck CJ, Muir JG, Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2014;8(7):819–34. https://doi.org/10.1586/17474124.2014.917956 .
doi: 10.1586/17474124.2014.917956
pubmed: 24830318
Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J, Hornova M, Srutkova D, Hudcovic T, Ridl J, Tlaskalova-Hogenova H. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS ONE. 2011;6(11):e27961. https://doi.org/10.1371/journal.pone.0027961 .
doi: 10.1371/journal.pone.0027961
pubmed: 22132181
pmcid: 3222668
Lindström C, Patel A, Prajapati JB, Holst O. Probiotic properties of exopolysaccharide producing lactic acid bacteria isolated from vegetables and traditional Indian fermented foods. Int J Ferment Foods. 2012;1(1):87–101. https://doi.org/10.1016/j.fbio.2013.10.002 .
doi: 10.1016/j.fbio.2013.10.002
Persborn M, Gerritsen J, Wallon C, Carlsson A, Akkermans LM, Söderholm JD. The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther. 2013;38(7):772–83. https://doi.org/10.1111/apt.12451 .
doi: 10.1111/apt.12451
pubmed: 23957603
Tsai YL, Lin TL, Chang CJ, Tsung-Ru W, Lai WF, Chia-Chen L, Lai HC. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019. https://doi.org/10.1186/s12929-018-0493-6 .
doi: 10.1186/s12929-018-0493-6
pubmed: 31699087
pmcid: 6836357
Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J. 2011;437(3):357–72. https://doi.org/10.1042/BJ20110326 .
doi: 10.1042/BJ20110326
pubmed: 21749321
Cantorna MT, Snyder L, Arora J. Vitamin A and vitamin D regulate the microbial complexity, barrier function, and the mucosal immune responses to ensure intestinal homeostasis. Crit Rev Biochem Mol Biol. 2019;54(2):184–92. https://doi.org/10.1080/10409238.2019.1611734 .
doi: 10.1080/10409238.2019.1611734
pubmed: 31084433
pmcid: 6629036
Lv Z, Wang Y, Yang T, Zhan X, Li Z, Hu H, Li T, Chen J. Vitamin A deficiency impacts the structural segregation of gut microbiota in children with persistent diarrhea. J Clin Biochem Nutr. 2016;59(2):113–21. https://doi.org/10.3164/jcbn.15-148 .
doi: 10.3164/jcbn.15-148
pubmed: 27698538
pmcid: 5018569
Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G208–16. https://doi.org/10.1152/ajpgi.00398.2007 .
doi: 10.1152/ajpgi.00398.2007
pubmed: 17962355
Raftery T, Martineau AR, Greiller CL, Ghosh S, McNamara D, Bennett K, Meddings J, O’Sullivan M. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. United Eur Gastroenterol J. 2015;3(3):294–302. https://doi.org/10.1177/2050640615572176 .
doi: 10.1177/2050640615572176
Cantorna MT, Nashold FE, Hayes CE. In vitamin A deficiency multiple mechanisms establish a regulatory T helper cell imbalance with excess Th1 and insufficient Th2 function. J Immunol. 1994;152(4):1515–22.
doi: 10.4049/jimmunol.152.4.1515
pubmed: 8120366
Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, O’Shea JJ. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood. 2008;111(3):1013–20. https://doi.org/10.1182/blood-2007-06-096438 .
doi: 10.1182/blood-2007-06-096438
pubmed: 17951529
pmcid: 2214761
Mielke LA, Jones SA, Raverdeau M, Higgs R, Stefanska A, Groom JR, Misiak A, Dungan LS, Sutton CE, Streubel G, Bracken AP, Mills KH. Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med. 2013;210(6):1117–24. https://doi.org/10.1084/jem.20121588 .
doi: 10.1084/jem.20121588
pubmed: 23690441
pmcid: 3674702
Van Immerseel F, Ducatelle R, De Vos M, Boon N, Van De Wiele T, Verbeke K, Rutgeerts P, Sas B, Louis P, Flint HJ. Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol. 2010;59(Pt 2):141–3. https://doi.org/10.1099/jmm.0.017541-0 .
doi: 10.1099/jmm.0.017541-0
pubmed: 19942690
Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619–25. https://doi.org/10.3945/jn.109.104638 .
doi: 10.3945/jn.109.104638
pubmed: 19625695
pmcid: 2728689
Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119. https://doi.org/10.1016/B978-0-12-800100-4.00003-9 .
doi: 10.1016/B978-0-12-800100-4.00003-9
pubmed: 24388214
Kretzmann NA, Fillmann H, Mauriz JL, Marroni CA, Marroni N, González-Gallego J, Tuñón MJ. Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm Bowel Dis. 2008;14(11):1504–13. https://doi.org/10.1002/ibd.20543 .
doi: 10.1002/ibd.20543
pubmed: 18623154
Coëffier M, Marion R, Ducrotté P, Déchelotte P. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr. 2003;22(4):407–13. https://doi.org/10.1016/s0261-5614(03)00040-2 .
doi: 10.1016/s0261-5614(03)00040-2
pubmed: 12880609
Chapman JC, Liu Y, Zhu L, Rhoads JM. Arginine and citrulline protect intestinal cell monolayer tight junctions from hypoxia-induced injury in piglets. Pediatr Res. 2012;72(6):576–82. https://doi.org/10.1038/pr.2012.137 .
doi: 10.1038/pr.2012.137
pubmed: 23041662
pmcid: 3976428
Valussi M. Functional foods with digestion-enhancing properties. Int J Food Sci Nutr. 2012;63(Suppl 1):82–9. https://doi.org/10.3109/09637486.2011.627841 .
doi: 10.3109/09637486.2011.627841
pubmed: 22010973
Park J, Choi TJ, Kang KS, Choi SH. The interrelationships between intestinal permeability and phlegm syndrome and therapeutic potential of some medicinal herbs. Biomolecules. 2021;11(2):284. https://doi.org/10.3390/biom11020284 .
doi: 10.3390/biom11020284
pubmed: 33671865
pmcid: 7918952
Ozaka S, Sonoda A, Ariki S, Minata M, Kamiyama N, Hidano S, Sachi N, Ito K, Kudo Y, Dewayani A, Chalalai T, Ozaki T, Soga Y, Fukuda C, Mizukami K, Ishizawa S, Nishiyama M, Fujitsuka N, Mogami S, Kubota K, Murakami K, Kobayashi T. Saireito, a Japanese herbal medicine, alleviates leaky gut associated with antibiotic-induced dysbiosis in mice. PLoS ONE. 2022;17(6):e0269698. https://doi.org/10.1371/journal.pone.0269698 .
doi: 10.1371/journal.pone.0269698
pubmed: 35704618
pmcid: 9200308
Huang X, Nie S, Xie M. Interaction between gut immunity and polysaccharides. Crit Rev Food Sci Nutr. 2017;57(14):2943–55. https://doi.org/10.1080/10408398.2015.1079165 .
doi: 10.1080/10408398.2015.1079165
pubmed: 26479888
You S, Hoskin R, Komarnytsky S, Moncada M. Mushrooms as functional and nutritious food ingredients for multiple applications. ACS Food Sci Technol. 2022;2:1184–95. https://doi.org/10.1021/acsfoodscitech.2c00107 .
doi: 10.1021/acsfoodscitech.2c00107
Clarke SF, Murphy EF, O’Sullivan O, Lucey AJ, Humphreys M, Hogan A, Hayes P, O’Reilly M, Jeffery IB, Wood-Martin R, Kerins DM, Quigley E, Ross RP, O’Toole PW, Molloy MG, Falvey E, Shanahan F, Cotter PD. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014;63(12):1913–20. https://doi.org/10.1136/gutjnl-2013-306541 .
doi: 10.1136/gutjnl-2013-306541
pubmed: 25021423
Barton W, Penney NC, Cronin O, Garcia-Perez I, Molloy MG, Holmes E, Shanahan F, Cotter PD, O’sullivan O. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut. 2018;67:625–33. https://doi.org/10.1136/gutjnl-2016-313627 .
doi: 10.1136/gutjnl-2016-313627
pubmed: 28360096
Dmytriv TR, Storey KB, Lushchak VI. Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise. Front Physiol. 2024;15:1380713. https://doi.org/10.3389/fphys.2024.1380713 .
doi: 10.3389/fphys.2024.1380713
pubmed: 39040079
pmcid: 11260943
Keirns BH, Koemel NA, Sciarrillo CM, Anderson KL, Emerson SR. Exercise and intestinal permeability: another form of exercise-induced hormesis? Am J Physiol Gastrointest Liver Physiol. 2020;319(4):G512–8. https://doi.org/10.1152/ajpgi.00232.2020 .
doi: 10.1152/ajpgi.00232.2020
pubmed: 32845171
Steelant B, Wawrzyniak P, Martens K, Jonckheere AC, Pugin B, Schrijvers R, Bullens DM, Vanoirbeek JA, Krawczyk K, Dreher A, Akdis CA, Hellings PW. Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. J Allergy Clin Immunol. 2019;144(5):1242-1253.e7. https://doi.org/10.1016/j.jaci.2019.04.027 .
doi: 10.1016/j.jaci.2019.04.027
pubmed: 31082457